Effects of Combination of SGLT-2 Inhibitor and GLP-1 Receptor Agonist on Renal Outcome in T2D with GFR below 30 and Macroalbuminuria : A Case Series

We hypothesized that the combination therapy of SGLT-2(Sodium-glucose co-transporter-2)inhibitor and Glucagon-like peptide-1 receptor agonist(GLP-1RA) provide renal protection in adults with T2D with estimated GFR (eGFR) below 30ml/minute/1.73 m2. We hereby describe four consecutively treated high renal risk patients with T2D with eGFR between 21 to 30ml/minute/1.73m2.